PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Small molecules - Market size and forecast 2018-2023 Biologics - Market size and forecast 2018-2023 Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Strong R&D of pipeline molecules Novel drug delivery system Increasing research funding PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Azurity Pharmaceuticals Inc. Celgene Corp. Eisai Co. Ltd. Helsinn Healthcare SA Horizon Therapeutics Plc Kyowa Kirin Co. Ltd. Merck & Co. Inc. Seattle Genetics Inc. Soligenix Inc. Takeda Pharmaceutical Co. Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market characteristics analysis Exhibit 06: Market segments Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Global mycosis fungoides therapeutics market pipeline: Overview Exhibit 20: Global mycosis fungoides therapeutics market pipeline: Snapshot Exhibit 21: Type - Market share 2018-2023 (%) Exhibit 22: Comparison by type Exhibit 23: Small molecules - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Small molecules - Year-over-year growth 2019-2023 (%) Exhibit 25: Biologics - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Biologics - Year-over-year growth 2019-2023 (%) Exhibit 27: Market opportunity by type Exhibit 28: Customer landscape Exhibit 29: Customer landscape analysis Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in North America Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Europe Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in Asia Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in ROW Exhibit 44: Key leading countries Exhibit 45: Market opportunity Exhibit 46: Decision framework Exhibit 47: Impact of drivers and challenges Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendor landscape analysis Exhibit 51: Vendors covered Exhibit 52: Vendor classification Exhibit 53: Market positioning of vendors Exhibit 54: Azurity Pharmaceuticals Inc. - Vendor overview Exhibit 55: Azurity Pharmaceuticals Inc. - Business segments Exhibit 56: Azurity Pharmaceuticals Inc. - Organizational developments Exhibit 57: Azurity Pharmaceuticals Inc. - Key offerings Exhibit 58: Azurity Pharmaceuticals Inc. - Key customers Exhibit 59: Celgene Corp. - Vendor overview Exhibit 60: Celgene Corp. - Business segments Exhibit 61: Celgene Corp. - Organizational developments Exhibit 62: Celgene Corp. - Geographic focus Exhibit 63: Celgene Corp. - Key offerings Exhibit 64: Celgene Corp. - Key customers Exhibit 65: Eisai Co. Ltd. - Vendor overview Exhibit 66: Eisai Co. Ltd. - Business segments Exhibit 67: Eisai Co. Ltd. - Organizational developments Exhibit 68: Eisai Co. Ltd. - Geographic focus Exhibit 69: Eisai Co. Ltd. - Segment focus Exhibit 70: Eisai Co. Ltd. - Key offerings Exhibit 71: Eisai Co. Ltd. - Key customers Exhibit 72: Helsinn Healthcare SA - Vendor overview Exhibit 73: Helsinn Healthcare SA - Business segments Exhibit 74: Helsinn Healthcare SA - Organizational developments Exhibit 75: Helsinn Healthcare SA - Key offerings Exhibit 76: Helsinn Healthcare SA - Key customers Exhibit 77: Horizon Therapeutics Plc - Vendor overview Exhibit 78: Horizon Therapeutics Plc - Business segments Exhibit 79: Horizon Therapeutics Plc - Organizational developments Exhibit 80: Horizon Therapeutics Plc - Geographic focus Exhibit 81: Horizon Therapeutics Plc - Segment focus Exhibit 82: Horizon Therapeutics Plc - Key offerings Exhibit 83: Horizon Therapeutics Plc - Key customers Exhibit 84: Kyowa Kirin Co. Ltd. - Vendor overview Exhibit 85: Kyowa Kirin Co. Ltd. - Business segments Exhibit 86: Kyowa Kirin Co. Ltd. - Organizational developments Exhibit 87: Kyowa Kirin Co. Ltd. - Geographic focus Exhibit 88: Kyowa Kirin Co. Ltd. - Segment focus Exhibit 89: Kyowa Kirin Co. Ltd. - Key offerings Exhibit 90: Kyowa Kirin Co. Ltd. - Key customers Exhibit 91: Merck & Co. Inc. - Vendor overview Exhibit 92: Merck & Co. Inc. - Business segments Exhibit 93: Merck & Co. Inc. - Organizational developments Exhibit 94: Merck & Co. Inc. - Geographic focus Exhibit 95: Merck & Co. Inc. - Segment focus Exhibit 96: Merck & Co. Inc. - Key offerings Exhibit 97: Merck & Co. Inc. - Key customers Exhibit 98: Seattle Genetics Inc. - Vendor overview Exhibit 99: Seattle Genetics Inc. - Business segments Exhibit 100: Seattle Genetics Inc. - Organizational developments Exhibit 101: Seattle Genetics Inc. - Key offerings Exhibit 102: Seattle Genetics Inc. - Key customers Exhibit 103: Soligenix Inc. - Vendor overview Exhibit 104: Soligenix Inc. - Business segments Exhibit 105: Soligenix Inc. - Organizational developments Exhibit 106: Soligenix Inc. - Segment focus Exhibit 107: Soligenix Inc. - Key offerings Exhibit 108: Soligenix Inc. - Key customers Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 115: Validation techniques employed for market sizing Exhibit 116: List of abbreviations Exhibit 117: Definition of market positioning of vendors

Azurity Pharmaceuticals Inc., Celgene Corp., Eisai Co. Ltd., Helsinn Healthcare SA, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Seattle Genetics Inc., Soligenix Inc., and Takeda Pharmaceutical Co. Ltd.